The c-Met pathway has been implicated in a variety of human
cancers for its critical role in
tumor growth, invasion, and
metastasis.
PF-04217903 is a novel
ATP-competitive small-molecule inhibitor of c-Met
kinase.
PF-04217903 showed more than 1,000-fold selectivity for c-Met compared with more than 150
kinases, making it one of the most selective c-Met inhibitors described to date.
PF-04217903 inhibited
tumor cell proliferation, survival, migration/invasion in MET-amplified cell lines in vitro, and showed marked antitumor activity in
tumor models harboring either MET gene amplification or a
hepatocyte growth factor (HGF)/c-Met autocrine loop at well-tolerated dose levels in vivo. Antitumor efficacy of
PF-04217903 was dose-dependent and showed a strong correlation with inhibition of c-Met phosphorylation, downstream signaling, and
tumor cell proliferation/survival. In human xenograft models that express relatively high levels of c-Met, complete inhibition of c-Met activity by
PF-04217903 only led to partial
tumor growth inhibition (38%-46%) in vivo. The combination of
PF-04217903 with
Recepteur d'origine nantais (RON)
short hairpin RNA (
shRNA) knockdown in the HT29 model that also expresses activated RON
kinase-induced
tumor cell apoptosis and resulted in enhanced antitumor efficacy (77%) compared with either
PF-04217903 (38%) or RON
shRNA alone (56%).
PF-04217903 also showed potent antiangiogenic properties in vitro and in vivo. Furthermore,
PF-04217903 strongly induced phospho-PDGFRβ (
platelet-derived growth factor receptor) levels in U87MG xenograft
tumors, indicating a possible oncogene switching mechanism in
tumor cell signaling as a potential resistance mechanism that might compromise
tumor responses to c-Met inhibitors. Collectively, these results show the use of highly selective inhibition of c-Met and provide insight toward targeting
tumors exhibiting different mechanisms of c-Met dysregulation.